Seattle Genetics junks SGN-15 cancer program, shifts focus

A Phase II trial of SGN-15 in combination with Taxotere against lung cancer demonstrated "an encouraging trend," but Seattle Genetics says it will dump any further research into the therapy in order to concentrate on others in its pipeline.

"Our clinical data confirm what we observed in our preclinical studies, which indicated that dosing SGN-15 prior to Taxotere enhances the therapeutic effect of the combination as compared to concurrent administration," said Clay B. Siegall, PhD, president and CEO at Seattle Genetics. "However, given the strength and diversity of the other products in our pipeline, we have decided not to continue development of SGN-15 and instead will evaluate out-licensing opportunities for the program."

- read this press release for more

Suggested Articles

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial. 

The purchase comes as AstraZeneca enters a 12-month period in which it plans to file for approval of about 10 assets.